Arteris, Inc.

AIP

CIK 0001667011 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$20M
↑+30.0% +$5Mvs FY2024 (Q4)
Operating Income
$4M
↑+181.5% +$3Mvs FY2024 (Q4)
Net Income
$4M
↑+1955.0% +$4Mvs FY2024 (Q4)
Gross Profit
$18M
↑+31.3% +$4Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
61/100
  • Profitability
    100ROIC 331.0% (10% = solid, 20%+ = moat)
  • Liquidity
    31Current Ratio 1.13 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    34Asset Turnover 0.64x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +30.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    100Op Margin -50.1% · trend +9.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project AIP's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

8%

Trailing CAGR unavailable; default 8%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$2.17
Total enterprise IV
$92M
Diluted shares
0.04B
Terminal PV
$67M (72% of total)
Year-5 FCF
$8M
YearProjected FCFDiscounted PV
+1$6M$5M
+2$6M$5M
+3$7M$5M
+4$7M$5M
+5$8M$5M
Terminal$107M$67M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$1M
investment in PP&E
Stock-based comp (TTM)
$18M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$115M
everything owned
Total liabilities
$130M
everything owed
Stockholders' equity
$-15M
shareholder claim

Recent performance · 22 quarters

Revenue↑+30.0% +$5M
$20M
Net Income↓-17.0% -$1M
$-9M
Free Cash Flow↑+6172.0% +$3M
$3M
Operating Margin↑+3.8pts
-50.1%

Drill down